TCM Lianhua Qingwen Capsule approved for registration in the Philippines
Yiling Pharmaceutical Co., Ltd. announced on Monday, August 10, that it has received a drug registration certificate issued by the Food and Drug Administration (FDA) of the Philippines, indicating Lianhua Qingwen Capsule has been registered in accordance with the standards for Traditionally-used Herbal Product.
As a leading product of Yiling Pharmaceutical Co., Ltd., Lianhua Qingwen products are mainly used for the treatment of cold and flu-related diseases, and have been listed in the diagnosis and treatment schemes for cold and flu-related diseases by the National Health Commission of China and National Administration of Traditional Chinese Medicine of China successively for many times. In 2020, Lianhua Qingwen Capsule / Granule has been listed as a recommended medicine for the epidemic in the Diagnosis and Treatment Scheme of Novel Coronavirus Pneumonia (Interim Versions #4-#7), issued officially by the related Chinese authorities. On April 12, 2020, the National Medical Products Administration of China approved that a new indication for "mild and common COVID-19" was added to Lianhua Qingwen Capsule/ Granule on the basis of its originally approved indications.
Up to now, Lianhua Qingwen Capsule has been approved for launching on the market in more than 10 countries and regions including Brazil, Indonesia, Canada, Romania, and Thailand.
The Department of Health (DOH) of the Philippines on August 10 (Monday) reported a single-day increase in new COVID-19 cases at 6,958. Based on DOH’s latest COVID-19 bulletin, the country’s coronavirus caseload stands at 161, 253 as of August 17, 2020.
Leave a reply →
